The MYLIP (myosin regulatory light chain interacting protein) gene is mapped to human chromosome 6p22.3. The encoded protein is an E3 ubiquitin ligase, expressed in all tissues including hippocampus and cerebellum. Anti-MYLIP antibody detects endogenous levels of total MYLIP protein.
Immunogen
The antiserum was produced against synthesized peptide derived from human MYLIP.
Immunogen Range: 161-210
Application
Anti-MYLIP antibody produced in rabbit has been used in western blot analysis.
Biochem/physiol Actions
MYLIP (myosin regulatory light chain interacting protein) controls the LDLR (low density lipoprotein receptor) activity and stability, which might change due to fluctuation in the intracellular cholesterol levels. Mylip is associated with brain development. It induces platelet-derived growth factor (PDGF) signaling in fibroblasts. Mylip is also called as inducible degrader of the LDL-R (Idol), as it leads to receptor degradation, especially in macrophages and liver. It might serve as a target for drug development in disease.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Molecular medicine reports, 18(3), 2780-2788 (2018-07-18)
Low‑density lipoprotein receptors (LDLRs) may serve a role in the diabetogenic effect of statins; however, the effects of statins on LDLR expression and its regulation in the pancreas and islets have yet to be determined. To exclude the long‑term effects
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 29(3), 538-543 (2013-10-30)
Nephrotic syndrome (NS) leads to elevation of serum total and LDL cholesterol. This is largely due to impaired LDL clearance, which is caused by hepatic LDL receptor (LDLR) deficiency despite normal LDLR mRNA expression, pointing to a post-transcriptional process. The
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
